Clinical Trial: Vouchers Vs. Prizes for Cocaine-Dependent Methadone Patients - 2

This study is not yet open for patient recruitment.
Verified by National Institute on Drug Abuse (NIDA) November 2005

Sponsors and Collaborators: National Institute on Drug Abuse (NIDA)
University of Connecticut
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00249535

Purpose

The purpose of this study is to compare voucher-based contingency management (CM) procedures to a lower-cost CM system that provides opportunities to win prizes. Cocaine-dependent outpatients are randomly assigned to (a) standard treatment, (b) standard treatment plus usual magnitude prize CM ($300), (c) standard treatment plus higher magnitude prize CM ($900), or (d) standard treatment plus voucher CM ($900). Urine and breath samples are collected 2-3x/week for 14 weeks. Follow-up interviews are conducted at 1,3,6 and 9 months following intake during which substance use and psychosocial functioning are assessed.
Condition Intervention
Contingency Management
 Behavior: Contingency management

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study

Official Title: Vouchers Vs. Prizes for Cocaine-Dependent Methadone Patients

Further study details as provided by National Institute on Drug Abuse (NIDA):
Primary Outcomes: Cocaine use
Expected Total Enrollment:  240

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion criteria: Each subject must meet the following criteria (1) age > 18 years, (2) current DSM-IV diagnosis of cocaine dependence, (3) received methadone treatment at the clinic for at least 3 months, (4) on a stable dose of methadone (no changes in dosing) for at least one month and not presently requesting a dose alteration, (5) submitted one or more clinic-collected cocaine positive urine samples in the previous 3 months, (6) English speaking, and (7) pass a brief quiz related to understanding of the informed consent form.

Exclusion criteria: Patients will be excluded if they (1) have a serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk), (2) have dementia (<23 on the Mini Mental State Exam; Folstein et al. 1975), or (3) are in recovery from pathological gambling.

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00249535

Sheila Alessi, Ph.D.      (860)679-1849    alessi@psychiatry.uchc.edu

Connecticut
      University of Connecticut Health Center, Farmington,  Connecticut,  06030,  United States
Nancy Petry, Ph.D.  860-679-2593    petry@psychiatry.uchc.edu 

Study chairs or principal investigators

Nancy Petry, Ph.D.,  Principal Investigator,  University of Connecticut   

More Information

Study ID Numbers:  NIDA-13444-2; R01-13444-2
Last Updated:  December 8, 2005
Record first received:  November 3, 2005
ClinicalTrials.gov Identifier:  NCT00249535
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2006-01-10



Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us